Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci?
Panagea
S
S
Perry
J D
JD
Gould
F K
FK
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000627:therapeutic use*; D006801:Humans; D055231:Lincosamides; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy*; D014769:Virginiamycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D055231:Lincosamides; D018942:Macrolides; D014769:Virginiamycin; D002981:Clindamycin; D004917:Erythromycin